PDCD1 and colorectal carcinoma: Therefore, we hypothesized that combination therapy, an herbal medicine as a human PD-1/PD-L1 interaction inhibitor plus Oxa for CRC treatment, would be a possible new complementary treatment with minimal side effects and would maximize the antitumor effect in patients with CRC.